Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02367911 · ClinicalTrials.gov registry record · Phase 3
A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis
A Phase 3 study of Plaque Psoriasis, sponsored by Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 144
- Enrollment target
- 9
- Study locations
NCT02367911 is a Phase 3 study of Plaque Psoriasis that has completed, run by Therapeutics. The registered enrollment target is 144 participants, below the 413-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (65% lower). The trial reports 9 study locations across 8 states.
The verdict
NCT02367911, a Phase 3 study of Plaque Psoriasis, has completed, sponsored by Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 144 participants
- Enrollment target
- 9
- Study locations
Study Summary
This Phase 3 study has been designed to determine and compare the efficacy and safety of 122-0551 Foam and Vehicle Foam applied twice daily for two weeks in subjects with plaque psoriasis.
Conditions Studied
Interventions
- DRUG Vehicle Foam
- DRUG 122-0551 Foam
Study Locations (9)
Indiana
- Shideler Clinical Research Center - Carmel
- The Indiana Clinical Trials Center, PC - Plainfield
Alabama
- Total Skin and Beauty Dermatology Center, PC - Birmingham
California
- UCSD Dermatology - San Diego
Florida
- Leavitt Medical Associates of Florida d/b/a Ameriderm Research - Ormond Beach
Michigan
- Henry Ford Health System - Detroit
Missouri
- MediSearch Clinical Trials - Saint Joseph
North Carolina
- Dermatology Consulting Services - High Point
Texas
- Arlington Research Center, Inc. - Arlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2015-01 |
| Est. Completion | 2017-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02367911
The ClinicalTrials.gov registry entry for NCT02367911 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 413-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (65% lower). The listed sponsor is Therapeutics, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Vehicle Foam is the first listed.
NCT02367911 reports 9 study locations spanning 8 distinct geographic areas - top geographies include Indiana, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT02367911 about?
NCT02367911 is a clinical study titled "A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis". This Phase 3 study has been designed to determine and compare the efficacy and safety of 122-0551 Foam and Vehicle Foam applied twice daily for two weeks in subjects with plaque psoriasis.
What is the current status of trial NCT02367911?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 144 participants. The study started on 2015-01. Estimated completion is 2017-02.
What conditions does trial NCT02367911 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT02367911?
The interventions under investigation include: Vehicle Foam (DRUG), 122-0551 Foam (DRUG).
Who is sponsoring clinical trial NCT02367911?
This trial is sponsored by Therapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02367911 being conducted?
This trial has 9 study locations across Alabama, California, Florida, Indiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
RECRUITING · Phase 3
-
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
ACTIVE NOT RECRUITING · Phase 3
-
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.